Dublin hosts stability center

Swiss pharma Helsinn has completed a 24-cubic-meter stability center at its Dublin facility. Stability chambers will operate at conditions dictated by the International Conference on Harmonization of 25 degrees C/60% relative humidity, 30 degrees C/65% RH, and 40 degrees C/75% RH.

The center also boasts a refrigerated chamber to store samples at 5 degrees C and a freezer for minus 20 degree C storage. The company says the new capability complements its work to optimize product formulations during development.

It will make available the center as a service for third party clients in addition to meetings its own pipeline requirements for commercial and development products. The center includes security monitoring and recording systems, as well as emergency power backup.

- see the release

Suggested Articles

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.

Boehringer Ingelheim is investing $50 million in an animal health plant in Puerto Rico, adding 105 jobs.

Teva will begin producing chemo drug vincristine in the U.S. but has resisted the idea that its withdrawal from the market led to a shortage.